Intravenous Treatment for CMV
For first-line IV treatment of CMV infection or disease, use IV ganciclovir 5 mg/kg every 12 hours (adjusted for renal function), which remains the standard of care despite newer oral alternatives. 1
First-Line IV Treatment Approach
The most recent 2025 ECIL-10 guidelines confirm that IV ganciclovir remains the primary first-line treatment for CMV disease and clinically significant CMV infection in transplant recipients 1. The standard dosing is:
- Induction therapy: 5 mg/kg IV every 12 hours
- Dose adjustment required for renal dysfunction (creatinine clearance-based nomogram)
- Duration: Continue until viral clearance documented by PCR or antigenemia testing
Critical Dosing Considerations for Renal Impairment
Patients with severe renal dysfunction require careful dose reduction 2:
- Creatinine ≥3.0 mg/dL: Reduce to 1.25 mg/kg/day for prophylaxis
- Creatinine ≥5.0 mg/dL: Further reduce to 1.25 mg/kg every other day
- Undialyzed patients with Cr >3.0 accumulate higher trough levels (3-8 μg/mL), necessitating aggressive dose reduction to prevent toxicity
Alternative IV Options
When Ganciclovir Cannot Be Used
IV foscarnet is the alternative when ganciclovir is contraindicated 1:
- Primary indication: Neutropenic patients who cannot tolerate ganciclovir's myelosuppression
- Also used for renal impairment when maribavir is unavailable or inappropriate
- Dosing: Standard induction 60 mg/kg IV every 8 hours or 90 mg/kg every 12 hours
Maribavir Considerations
While maribavir is now available, the 2025 ECIL-10 guidelines position it specifically for 1:
- Neutropenic patients unable to receive valganciclovir (oral) or ganciclovir (IV)
- Renal dysfunction when foscarnet is inappropriate
- Important limitation: Maribavir showed non-inferiority failure versus valganciclovir in first-line therapy (69.6% vs 77.4% clearance), so it's not preferred as initial IV treatment
Sequential IV-to-Oral Strategy
After 5 days of IV ganciclovir, transition to oral valganciclovir 900 mg twice daily is effective and reduces hospitalization 3:
- Achieves comparable drug exposure to continued IV therapy
- Allows outpatient management after initial stabilization
- Total treatment duration typically 21 days minimum, guided by viral load monitoring
Resistant or Refractory CMV
If CMV persists or progresses after 2 weeks of first-line therapy 1:
- Check genotypic resistance testing immediately
- For high-resistance mutations (IC₅₀ >5-fold increase):
- Switch to IV foscarnet as monotherapy
- Consider combination foscarnet + high-dose ganciclovir (7.5-10 mg/kg q12h) for severe disease
- For low-resistance mutations (IC₅₀ 2-5-fold increase):
- Maribavir is now the preferred second-line agent (superior response rate and lower organ toxicity than alternatives)
- Critical caveat: Do NOT use maribavir for CNS or ocular CMV disease due to poor penetration
Key Pitfalls to Avoid
- Do not underdose in renal failure: Use standardized nomograms, but monitor trough levels in severe dysfunction (Cr >3.0) as accumulation still occurs despite adjustment 2
- Do not use letermovir for treatment: It is prophylaxis-only; not indicated for active infection or disease 1
- Do not combine maribavir with ganciclovir/valganciclovir: This combination is specifically not recommended 1
- Monitor for neutropenia aggressively: Primary toxicity of ganciclovir; check CBC twice weekly during induction
- Verify viral clearance before stopping: Continue treatment until PCR negativity, not just clinical improvement
Special Populations
Pediatric patients (age <12 years): Same ganciclovir dosing as adults (5 mg/kg q12h); maribavir not FDA-approved below age 12 1
High-risk patients requiring longer therapy include 2:
- Donor CMV+/Recipient CMV- (D+/R-)
- Liver transplant recipients
- Patients with ≥6 HLA mismatches (renal transplant)
These patients may need extended treatment beyond standard 21 days and consideration of secondary prophylaxis after completing therapy.